Components of the Lectin Pathway of Complement in Solid Tumour Cancers
Abstract
:Simple Summary
Abstract
1. Introduction
2. Gynaecological Cancers
3. Lung Cancer
4. Alimentary Tract Cancers
5. Other Solid Tumours
6. Concluding Remarks
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Ehrnthaller, C.; Ignatius, A.; Gebhard, F.; Huber-Lang, M. New insights of an old defense system: Structure, function, and clinical relevance of the complement system. Mol. Med. 2011, 17, 317–329. [Google Scholar] [CrossRef] [PubMed]
- Nesargikar, P.N.; Spiller, B.; Chavez, R. The complement system: History, pathways, cascade and inhibitors. Eur. J. Microbiol. Immunol. 2012, 2, 103–111. [Google Scholar] [CrossRef] [PubMed]
- Roumenina, L.T.; Daugan, M.V.; Petitprez, F.; Sautes-Fridman, C.; Fridman, W.H. Context-dependent roles of complement in cancer. Nat. Rev. Cancer 2019, 19, 698–715. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rutkowski, M.J.; Sughrue, M.E.; Kane, A.J.; Millis, S.A.; Parsa, A.T. Cancer and the complement cascade. Mol. Cancer Res. 2010, 8, 1453–1465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mamidi, S.; Hone, S.; Kirschfink, M. The complement system in cancer: Ambivalence between tumour destruction and promotion. Immunobiology 2017, 222, 45–54. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.-Y.; Wang, X.-Y.; Li, R.-Y.; Jia, S.-C.; Sun, P.; Zhao, M. Recent progress in the understanding of complement activation and its role in tumor growth and anti-tumor therapy. Biomed. Pharmacother. 2017, 91, 448–456. [Google Scholar] [CrossRef] [PubMed]
- Revel, M.; Daugan, M.V.; Sautes-Fridman, C.; Fridman, W.H.; Roumenina, L.T. Complement system: Promoter or suppressor of cancer progression? Antibodies 2020, 9, 57. [Google Scholar] [CrossRef]
- Cedzyński, M.; Świerzko, A.S. Components of the lectin pathway of complement in haematologic malignancies. Cancers 2020, 12, 1792. [Google Scholar] [CrossRef]
- Dobo, J.; Szakacs, D.; Oroszlan, G.; Kortvely, E.; Kiss, B.; Boros, E.; Szasz, R.; Zavodszky, P.; Gal, P.; Pal, G. MASP-3 is the exclusive pro-factor D activator in resting blood: The lectin and the alternative complement pathways are fundamentally linked. Sci. Rep. 2016, 6, 31877. [Google Scholar] [CrossRef] [Green Version]
- Hayashi, M.; Machida, T.; Ishida, Y.; Ogata, Y.; Omori, T.; Takasumi, M.; Endo, Y.; Suzuki, T.; Sekimata, M.; Homma, Y.; et al. Cutting edge: Role of MASP-3 in the physiological activation of factor D of the alternative complement pathway. J. Immunol. 2019, 203, 1411–1416. [Google Scholar] [CrossRef]
- Holers, M.V.; Borodovsky, A.; Scheinman, R.I.; Ho, N.; Ramos Ramirez, J.; Dobo, J.; Gal, P.; Lindenberger, J.; Hansen, A.G.; Desai, D.; et al. Key components of the complement lectin pathway are not only required for the development of inflammatory arthritis but also regulate the transcription of factor D. Front. Immunol. 2020, 11, 201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krarup, A.; Wallis, R.; Presanis, J.S.; Gal, P.; Sim, R.B. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2007, 2, e623. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krarup, A.; Gulla, K.C.; Gal, P.; Hajela, K.; Sim, R.B. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. Biochim. Biophys. Acta 2008, 1784, 1294–1300. [Google Scholar] [CrossRef] [PubMed]
- Gulla, K.C.; Gupta, K.; Krarup, A.; Gal, P.; Schwaeble, W.J.; Sim, R.B.; O’Connor, C.D.; Hajela, K. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 2010, 129, 482–495. [Google Scholar] [CrossRef]
- Dobo, J.; Major, B.; Kekesi, K.A.; Szabo, I.; Megyeri, M.; Hajela, K.; Juhasz, G.; Zavodszky, P.; Gal, P. Cleavage of kininogen and subsequent bradykinin release by the complement component: Mannose-binding lectin-associated serine protease (MASP)-1. PLoS ONE 2011, 6, e20036. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yongqing, T.; Drentin, N.; Duncan, R.C.; Wijeyewickrema, L.C.; Pike, R.N. Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: Two genes, five proteins and many functions? Biochim. Biophys. Acta 2012, 1824, 253–262. [Google Scholar] [CrossRef]
- Hess, K.; Ajjan, R.; Phoenix, F.; Dobó, J.; Gál, P.; Schroeder, V. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS ONE 2012, 7, e35690. [Google Scholar] [CrossRef]
- Kozarcanin, H.; Lood, C.; Munthe-Fog, L.; Sandholm, K.; Hamad, O.A.; Bengtsson, A.A.; Skjoedt, M.O.; Huber-Lang, M.; Garred, P.; Nilsson-Ekdahl, K.; et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J. Thromb. Haemost. 2016, 14, 531–545. [Google Scholar] [CrossRef]
- Jenny, L.; Noser, D.; Larsen, J.B.; Dobo, J.; Gal, P.; Pal, G.; Schroeder, V. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots. Mol. Immunol. 2019, 114, 1–9. [Google Scholar] [CrossRef]
- Dobo, J.; Harmat, V.; Beinrohr, L.; Sebestyen, E.; Zavodszky, P.; Gal, P. MASP-1, a promiscuous complement protease: Structure of its catalytic region reveals the basis of its broad specificity. J. Immunol. 2009, 183, 1207–1214. [Google Scholar] [CrossRef] [Green Version]
- Megyeri, M.; Mako, V.; Beinrohr, L.; Doleschall, Z.; Prohaszka, Z.; Cervenak, L.; Zavodszky, P.; Gal, P. Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function. J. Immunol. 2009, 183, 3409–3416. [Google Scholar] [CrossRef] [PubMed]
- Jani, P.K.; Kajdacsi, E.; Megyeri, M.; Dobo, J.; Doleschall, Z.; Futosi, K.; Timar, C.I.; Mocsai, A.; Mako, V.; Gal, P.; et al. MASP-1 induces a unique cytokine pattern in endothelial cells: A novel link between complement system and neutrophil granulocytes. PLoS ONE 2014, 9, e87104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schwaner, E.; Nemeth, Z.; Jani, P.K.; Kajdacsi, E.; Debreczeni, M.L.; Doleschall, Z.; Dobo, J.; Gal, P.; Rigo, J.; Andras, K.; et al. Transcriptome analysis of inflammation-related gene expression in endothelial cells activated by complement MASP-1. Sci. Rep. 2017, 7, 10462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Debreczeni, M.L.; Nemeth, Z.; Kajdacsi, E.; Schwaner, E.; Mako, V.; Masszi, A.; Doleschall, Z.; Rigo, J.; Walter, F.R.; Deli, M.A.; et al. MASP-1 increases endothelial permeability. Front. Immunol. 2019, 10, 991. [Google Scholar] [CrossRef]
- Swierzko, A.S.; Florczak, K.; Cedzynski, M.; Szemraj, J.; Wydra, D.; Bak-Romaniszyn, L.; Emerich, J.; Sułowska, Z. Mannan-binding lectin (MBL) in women with tumours of the reproductive system. Cancer Immunol. Immunother. 2007, 56, 959–971. [Google Scholar] [CrossRef]
- Swierzko, A.S.; Szala, A.; Sawicki, S.; Szemraj, J.; Sniadecki, M.; Sokolowska, A.; Kaluzynski, A.; Wydra, D.; Cedzynski, M. Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours. Cancer Immunol. Immunother. 2014, 63, 1129–1140. [Google Scholar] [CrossRef] [Green Version]
- Nevadunsky, N.S.; Korneeva, I.; Caputo, T.; Witkin, S.S. Mannose-binding lectin codon 54 genetic polymorphism and vaginal protein levels in women with gynecologic malignancies. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012, 163, 216–218. [Google Scholar] [CrossRef] [Green Version]
- Szala, A.; Sawicki, S.; Swierzko, A.S.; Szemraj, J.; Sniadecki, M.; Michalski, M.; Kaluzynski, A.; Lukasiewicz, J.; Maciejewska, A.; Wydra, D.; et al. Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours. Cancer Immunol. Immunother. 2013, 62, 1411–1419. [Google Scholar] [CrossRef] [Green Version]
- Suryawanshi, S.; Huang, X.; Elishaev, E.; Budiu, R.A.; Zhang, L.; Kim, S.H.; Donnellan, N.; Mantia-Smaldone, G.; Ma, T.; Tseng, G.; et al. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin. Cancer Res. 2014, 20, 6163–6174. [Google Scholar] [CrossRef] [Green Version]
- Jang, H.; Jun, Y.; Kim, S.; Jung, Y.; Jo Park, B.; Lee, J.; Kim, J.; Lee, S.; Kim, J. FCN3 functions as a tumor suppressor of lung adenocarcinoma through induction of endoplasmic reticulum stress. Cell Death Dis. 2021, 12, 407. [Google Scholar] [CrossRef]
- Sipos, A.; Ujlaki, G.; Miko, E.; Maka, E.; Szabo, J.; Uray, K.; Krasznai, Z.; Bai, P. The role of microbiome in ovarian cancer: Mechanistic Insights into oncobiosis and to bacterial metabolite signaling. Mol. Med. 2021, 27, 33. [Google Scholar] [CrossRef]
- Alizadehmohajer, N.; Shojaeifar, S.; Nedaeinia, R.; Esparvarinha, M.; Mohammadi, F.; Ferns, G.A.; Ghayour-Mobarhan, M.; Manian, M.; Balouchi, A. Association between the microbiota and women’s cancers—Cause or consequences? Biomed. Pharmacother. 2020, 127, 110203. [Google Scholar] [CrossRef]
- Borella, F.; Carosso, A.R.; Cosma, S.; Preti, M.; Collemi, G.; Cassoni, P.; Bertero, L.; Benedetto, C. Gut microbiota and gynecological cancers: A summary of pathogenic mechanisms and future directions. ACS Infect. Dis. 2021, 7, 987–1009. [Google Scholar] [CrossRef] [PubMed]
- Banerjee, S.; Tian, T.; Wei, Z.; Shih, N.; Feldman, F.D.; Alwine, J.C.; Coukos, G.; Robertson, E.S. The ovarian cancer oncobiome. Oncotarget 2017, 22, 36225–36245. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, H.L.; Lu, X.; Yang, X.; Xu, N. Association of MBL2 exon 1 polymorphisms with high-risk papillomavirus infection and cervical cancers: A meta-analysis. Arch. Gynecol. Obstet. 2016, 294, 1109–1116. [Google Scholar] [CrossRef] [PubMed]
- Siamakpour-Reihani, S.; Patterson Cobb, L.; Jiang, C.; Zhang, D.; Previs, R.A.; Owzar, K.; Nixon, A.B.; Alvarez Secord, A. Differential expression of immune related genes in high-grade ovarian serous carcinoma. Gynecol. Oncol. 2020, 156, 662–668. [Google Scholar] [CrossRef]
- Sahar, T.; Nigam, A.; Anjum, S.; Gupta, N.; Wajid, S. Secretome profiling and computational biology of human leiomyoma samples unravel molecular signatures with potential for diagnostic and therapeutic interventions. Reprod. Sci. 2021, 28, 2672–2684. [Google Scholar] [CrossRef]
- Kaur, D.; Arora, C.; Raghava, G.P.S. Pattern recognition receptor based prognostic biomarkers for predicting survival of uterine corpus endometrial cancer patients. Mol. Diagn. Ther. 2021, 25, 629–646. [Google Scholar] [CrossRef]
- Kong, L.; Wang, J.; Cheng, J.; Zang, C.; Chen, F.; Wang, W.; Zhao, H.; Wang, Y.; Wang, D. Comprehensive identification of the human secretome as potential indicators in treatment outcome of HPV-positive and -negative cervical cancer patients. Gynecol. Obstet. Investig. 2020, 85, 405–415. [Google Scholar] [CrossRef]
- Maestri, C.A.; Nisihara, R.; Mendes, H.W.; Jensenius, J.; Thiel, S.; Messias-Reason, I.; de Carvalho, N.S. MASP-1 and MASP-2 serum levels are associated with worse prognostic in cervical cancer progression. Front. Immunol. 2018, 9, 2742. [Google Scholar] [CrossRef]
- Andersen, J.D.; Boylan, K.L.M.; Xue, F.S.; Anderson, L.B.; Witthuhn, B.A.; Markowski, T.W.; Higgins, L.A.; Skubitz, A.P.N. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 2010, 31, 559–610. [Google Scholar] [CrossRef] [PubMed]
- Vasquez-Ortiz, G.; Ciudad, C.J.; Pina, P.; Vazquez, K.; Hidalgo, A.; Alatorre, B.; Garcia, J.A.; Salamanca, F.; Peralta-Rodriguez, R.; Rangel, A.; et al. Gene identification by cDNA arrays in HPV-positive cervical cancer. Arch. Med. Res. 2005, 36, 448–458. [Google Scholar] [CrossRef] [PubMed]
- Guo, X.; Hao, Y.; Kamilijiang, M.; Hasimu, A.; Yuan, J.; Wu, G.; Reyimu, H.; Kadeer, N.; Abudula, A. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis. Tumor Biol. 2015, 36, 1711–1720. [Google Scholar] [CrossRef] [PubMed]
- Saldova, R.; Wormald, M.R.; Dwek, R.A.; Rudd, P.M. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis. Markers. 2008, 25, 219–232. [Google Scholar] [CrossRef]
- Zhou, M.; Kong, Y.; Wang, Z.; Li, W.; Chen, S.; Wang, L.; Wang, C.; Zhang, Q. LC-MS/MS-based quantitative proteomics analysis of different stages of non-small-cell lung cancer. BioMed Res. Int. 2021, 2021, 5561569. [Google Scholar] [CrossRef]
- Kang, J.U.; Koo, S.H.; Kwon, K.C.; Park, J.W.; Kim, J.M. Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 2009, 9, 237. [Google Scholar] [CrossRef] [Green Version]
- Chen, Y.; Wu, E.-D.; Ma, S.; Bai, W.-Q.; Yin, Y.-J.; Shi, G.-L. The clinical significance of serum MASP-2 and IDH1 in the early diagnosis of non-small cell lung cancer. Clin. Lab. 2020, 66. [Google Scholar] [CrossRef]
- Wang, F.-Y.; Tahara, T.; Arisawa, T.; Shibata, T.; Yamashita, H.; Nakamura, M.; Yoshioka, D.; Okubo, M.; Maruyama, N.; Kamano, T.; et al. Mannan-binding lectin (MBL) polymorphism and gastric cancer risk in Japanese population. Dig. Dis. Sci. 2008, 53, 2904–2908. [Google Scholar] [CrossRef]
- Baccarelli, A.; Hou, L.; Chen, J.; Lissowska, J.; El-Omar, E.M.; Grillo, P.; Giacomini, S.M.; Yaeger, M.; Bernig, T.; Zatonski, W.; et al. Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int. J. Cancer 2006, 119, 1970–1975. [Google Scholar] [CrossRef]
- Scudiero, O.; Nardone, G.; Omodei, D.; Tatangelo, F.; Vitale, D.F.; Salvatore, F.; Castaldo, G. A mannose-binding lectin-defective haplotype is a risk factor for gastric cancer. Clin. Chem. 2006, 52, 1625–1626. [Google Scholar] [CrossRef] [Green Version]
- Su, C.; Lin, Y.; Cai, L.; Niu, J. Association between mannose-binding lectin variants, haplotypes and risk of hepatocellular carcinoma: A case-control study. Sci. Rep. 2016, 6, 321467. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, C.-Y.; Dong, J.-F.; Chen, Z.-Q.; Ding, G.-S.; Fu, Z.-R. MiR-942-3p promotes the proliferation and invasion of hepatocellular carcinoma cells by targeting MBL2. Cancer Control 2019, 26, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Awan, F.M.; Naz, A.; Obaid, A.; Ali, A.; Ahmad, J.; Anjum, S.; Janjua, H.A. Identification of circulating biomarker candidates for hepatocellular carcinoma (HCC): An integrated prioritization approach. PLoS ONE 2015, 10, e0138913. [Google Scholar] [CrossRef] [PubMed]
- Zhang, B.; Wu, H. Decreased expression of COLEC10 predicts poor overall survival in patients with hepatocellular carcinoma. Cancer Manag. Res. 2018, 10, 2369–2375. [Google Scholar] [CrossRef] [Green Version]
- Bai, K.-H.; He, S.-Y.; Shu, L.-L.; Wang, W.-D.; Lin, S.-Y.; Zhang, Q.-Y.; Li, L.; Cheng, L.; Dai, Y.-J. Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index. Cancer Med. 2020, 9, 4290–4298. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, T.; Hu, Y.; Ding, Q.; Yu, Y.; Wang, F.; Luo, F.; Zhang, X.-L. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases. Virol. Sin. 2015, 30, 249–260. [Google Scholar] [CrossRef] [PubMed]
- Hu, Y.-L.; Luo, F.-L.; Fu, J.-L.; Chen, T.-L.; Wu, S.-M.; Zhou, Y.-D.; Zhang, X.-L. Early increased ficolin-2 concentrations are associated with severity of liver inflammation and efficacy of anti-viral therapy in chronic hepatitis C patients. Scand. J. Immunol. 2013, 77, 144–150. [Google Scholar] [CrossRef]
- Liu, J.; Ali, M.A.M.; Shi, Y.; Zhao, Y.; Luo, F.; Yu, J.; Xiang, T.; Tang, J.; Li, D.; Hu, Q.; et al. Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell. Mol. Immunol. 2009, 6, 235–244. [Google Scholar] [CrossRef] [Green Version]
- Hamed, M.R.; Brown, R.J.; Zothner, C.; Urbanowicz, R.A.; Mason, C.P.; Krarup, A.; McClure, C.P.; Irving, W.L.; Ball, J.K.; Harris, M.; et al. Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. J. Innate Immun. 2014, 6, 676–684. [Google Scholar] [CrossRef]
- Zhao, Y.; Ren, Y.; Zhang, X.; Zhao, P.; Tao, W.; Zhong, J.; Li, Q.; Zhang, X.-L. Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape. J. Immunol. 2014, 193, 783–796. [Google Scholar] [CrossRef] [Green Version]
- Yang, G.; Liang, Y.; Zheng, T.; Song, R.; Wang, J.; Shi, H.; Sun, B.; Xie, C.; Li, Y.; Han, J.; et al. FCN2 inhibits epithelial-mesenchymal transition-induced metastasis of hepatocellular carcinoma via TGF-β/Smad signalling. Cancer Lett. 2016, 378, 80–86. [Google Scholar] [CrossRef] [PubMed]
- Luo, J.H.; Ren, B.; Keryanov, S.; Tseng, G.C.; Rao, U.N.M.; Monga, S.P.; Strom, S.; Demetris, A.J.; Nalesnik, M.; Yu, Y.P.; et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006, 44, 1012–1024. [Google Scholar] [CrossRef] [PubMed]
- Ferrin, G.; Ranchal, I.; Llamosa, C.; Rodriguez-Peralvarez, M.L.; Romero-Ruiz, A.; Aguilar-Melero, P.; Lopez-Cillero, P.; Briceno, J.; Muntane, J.; Montero-Alvarez, J.L.; et al. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE. Liver Int. 2014, 34, 438–446. [Google Scholar] [CrossRef] [PubMed]
- Jalal, P.J.; King, B.J.; Saeed, A.; Adedeji, Y.; Mason, C.P.; Ball, J.K.; Irving, W.L.; McClure, C.P.; Tarr, A.W. Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection. Virology 2019, 530, 99–106. [Google Scholar] [CrossRef] [PubMed]
- Eurich, D.; Boas-Knoop, S.; Morawietz, L.; Neuhaus, R.; Somasundaram, R.; Ruehl, M.; Neumann, U.P.; Neuhaus, P.; Bahra, M.; Seehofer, D. Association of mannose-binding lectin-2 gene polymorphism with the development of hepatitis C-induced hepatocellular carcinoma. Liver Int. 2011, 31, 1006–1012. [Google Scholar] [CrossRef]
- Gu, X.; Ji, Q.; Wang, H.; Jiang, M.; Yang, J.; Fang, M.; Wang, M.; Gao, C. Genetic variants of mannose-binding lectin 2 gene influence progression and prognosis of patients with hepatitis B virus infection in China. Clin. Res. Hepatol. Gastroenterol. 2016, 40, 614–621. [Google Scholar] [CrossRef]
- Lin, Y.; Su, C.; Niu, J.; Guo, Z.; Cai, L. Impact of mannose-binding lectin polymorphism on the risk of hepatocellular carcinoma: A case-control study in Chinese Han population. J. Epidemiol. 2015, 25, 387–391. [Google Scholar] [CrossRef] [Green Version]
- Rong, Y.; Jin, D.; Hou, C.; Hu, J.; Wu, W.; Ni, X.; Wang, D.; Lou, W. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: Up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol. 2010, 10, 68. [Google Scholar] [CrossRef] [Green Version]
- Aykut, B.; Pushalkar, S.; Chen, R.; Li, Q.; Abengozar, R.; Kim, J.I.; Shadaloey, S.A.; Wu, D.; Preiss, P.; Verma, N.; et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 2019, 574, 264–267. [Google Scholar] [CrossRef]
- Ytting, H.; Jensenius, J.C.; Christensen, I.J.; Thiel, S.; Nielsen, H.J. Increased activity of the mannan-binding lectin complement pathway in patients with colorectal cancer. Scand. J. Gastroenterol. 2004, 39, 674–679. [Google Scholar] [CrossRef]
- Ytting, H.; Christensen, I.J.; Jensenius, J.C.; Thiel, S.; Nielsen, H.J. Preoperative mannan-binding lectin pathway and prognosis in colorectal cancer. Cancer Immunol. Immunother. 2005, 54, 265–272. [Google Scholar] [CrossRef] [PubMed]
- Ytting, H.; Christensen, I.J.; Steffensen, R.; Alsner, J.; Thiel, S.; Jensenius, J.C.; Hansen, U.; Nielsen, H.J. Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) genotypes in colorectal cancer. Scand. J. Immunol. 2011, 73, 122–127. [Google Scholar] [CrossRef] [PubMed]
- Lu, S.; Bevier, M.; Huhn, S.; Sainz, J.; Lascorz, J.; Pardini, B.; Naccarati, A.; Vodickova, L.; Novotny, J.; Hemminki, K.; et al. Genetic variants in C-type lectin genes are associated with colorectal cancer susceptibility and clinical outcome. Int. J. Cancer 2013, 133, 2325–2333. [Google Scholar] [CrossRef] [PubMed]
- Zanetti, K.A.; Haznader, M.; Welsh, J.A.; Robles, A.I.; Ryan, B.M.; McClary, A.C.; Bowman, E.D.; Goodman, J.E.; Bernig, T.; Chanock, S.J.; et al. 3′UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res. 2012, 72, 1467–1477. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sarvari, J.; Mojtahedi, Z.; Kuramitsu, Y.; Fattahi, M.R.; Ghaderi, A.; Nakamura, K.; Erfani, E. Comparative proteomics of sera from HCC patients with different origins. Hepat. Mon. 2014, 14, e13103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shen, S.; Peng, H.; Wang, Y.; Xu, M.; Xie, X.; Peng, B.; Kuang, M. Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis. BMC Cancer 2018, 18, 117. [Google Scholar] [CrossRef] [Green Version]
- Troldborg, A.; Hansen, A.; Hansen, S.W.K.; Jensenius, J.C.; Stengaard-Pedersen, K.; Thiel, S. Lectin complement pathway proteins in healthy individuals. Clin. Exp. Immunol. 2017, 188, 138–147. [Google Scholar] [CrossRef] [Green Version]
- Świerzko, A.S.; Michalski, M.; Sokołowska, A.; Nowicki, M.; Szala-Poździej, A.; Eppa, Ł.; Mitrus, I.; Szmigielska-Kapłon, A.; Sobczyk-Kruszelnicka, M.; Michalak, K.; et al. Associations of ficolins with haematological malignancies in patients receiving high-dose chemotherapy and autologous haematopoietic stem cell transplantations (auto-HSCT). Front. Immunol. 2020, 10, 3097. [Google Scholar] [CrossRef]
- Frederiksen, K.; Krag, A.E.; Larsen, J.B.; Kiil, B.J.; Thiel, S.; Hvas, A.-M. Remote ischemic preconditioning does not influence lectin pathway protein levels in head and neck cancer patients undergoing surgery. PLoS ONE 2020, 15, e0230411. [Google Scholar] [CrossRef] [Green Version]
- Sokołowska, A.; Świerzko, A.S.; Gajek, G.; Gołos, A.; Michalski, M.; Nowicki, M.; Szala-Poździej, A.; Wolska-Washer, A.; Brzezińska, O.; Wierzbowska, A.; et al. Associations of ficolins and mannose-binding lectin with acute myeloid leukaemia in adults. Sci. Rep. 2020, 10, 10561. [Google Scholar] [CrossRef]
- Kitamura, F.; Miyata, T.; Uemura, N.; Uchihara, T.; Imai, K.; Hayashi, H.; Yamashita, Y.-I.; Matsusaki, K.; Ishimoto, T.; Baba, H. Proteomic analysis of malignant ascites from patients with pancreatic ductal adenocarcinoma. Anticancer Res. 2021, 41, 2895–2900. [Google Scholar] [CrossRef] [PubMed]
- Verma, A.; Matta, A.; Shukla, N.K.; Deo, S.V.; Gupta, S.D.; Ralhan, R. Clinical significance of mannose-binding lectin-associated protease-2 expression in esophageal squamous cell carcinoma. Int. J. Cancer 2006, 118, 2930–2935. [Google Scholar] [CrossRef] [PubMed]
- Hirano, M.; Ma, B.Y.; Kawaski, N.; Okimura, K.; Baba, M.; Nakagawa, T.; Miwa, K.; Kawasaki, N.; Oka, S.; Kawasaki, T. Mannan-binding protein blocks the activation of metalloproteases meprin alpha and beta. J. Immunol. 2005, 175, 3177–3185. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shi, Y.; Liu, G.; Zhang, H.; Yu, P.; Xiang, X.; Lu, Y.; Dong, X.; Li, X. Expressions and clinical significance of mannose-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) in patients with thyroid neoplasm. Chin.-Ger. J. Clin. Oncol. 2013, 12, P106–P108. [Google Scholar] [CrossRef]
- Fisch, U.P.; Zehnder, A.; Hirt, A.; Niggli, F.K.; Simon, A.; Ozsahin, H.; Schlapbach, L.J.; Ammann, R.A. Mannan-binding lectin (MBL) and MBL-associated serine protease 2 in children with cancer. Swiss Med. Wkly. 2011, 141, w13191. [Google Scholar] [CrossRef] [Green Version]
- Arellano-Garcia, M.E.; Li, R.; Liu, X.; Xie, Y.; Yan, X.; Loo, J.A.; Hu, S. Identification of a tetranectin as a potential biomarker for metastatic oral cancer. Int. J. Mol. Sci. 2010, 11, 3106–3121. [Google Scholar] [CrossRef]
- Reis, E.S.; Mastellos, D.C.; Ricklin, D.; Mantovani, A.; Lambris, J.D. Complement in cancer: Untangling an intricate relationship. Nat. Rev. Immunol. 2018, 18, 5–18. [Google Scholar] [CrossRef]
- Zhang, R.; Liu, Q.; Li, T.; Liao, Q.; Zhao, Y. Role of the complement system in the tumour microenvironment. Cancer Cell Int. 2019, 19, 300. [Google Scholar] [CrossRef]
- Okrój, M.; Potempa, J. Complement activation as a helping hand for inflammophilic pathogens and cancer. Front. Immunol. 2019, 9, 3125. [Google Scholar] [CrossRef] [Green Version]
- Sinha, A.; Singh, V.; Tandon, R.; Srivastava, L.M. Dichotomy of complement system: Tumorigenesis or destruction. Immunol. Lett. 2020, 223, 89–96. [Google Scholar] [CrossRef]
- Lu, P.; Ma, Y.; Wei, S.; Liang, X. The dual role of complement in cancers, from destroying tumors to promoting tumor development. Cytokine 2021, 143, 155522. [Google Scholar] [CrossRef] [PubMed]
- Bareke, H.; Akbuga, J. Complement system’s role in cancer and its therapeutic potential in ovarian cancer. Scand. J. Immunol. 2018, 88, e12672. [Google Scholar] [CrossRef] [PubMed]
- Kourtzelis, I.; Rafail, S. The dual role of complement in cancer and its implication in anti-tumor therapy. Ann. Transl. Med. 2016, 4, 265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Afshar-Kharghan, V. The role of the complement system in cancer. J. Clin. Investig. 2017, 127, 780–789. [Google Scholar] [CrossRef] [Green Version]
- O’Brien, R.M.; Cannon, A.; Reynolds, J.V.; Lusaght, J.; Lynam-Lennon, N. Complement in tumourigenesis and the response to cancer therapy. Cancers 2021, 13, 1209. [Google Scholar] [CrossRef]
- Storm, L.; Christensen, I.J.; Jensenius, J.C.; Nielsen, H.J.; Thiel, S.; Danish Study Group on Early Detection of Colorectal Cancer. Evaluation of complement proteins as screening markers for colorectal cancer. Cancer Immunol. Immunother. 2015, 64, 41–50. [Google Scholar] [CrossRef]
- Ytting, H.; Christensen, I.J.; Thiel, S.; Jensenius, J.C.; Nielsen, H.J. Serum mannan-binding lectin-associated serine protease 2 levels in colorectal cancer: Relation to recurrence and mortality. Clin. Cancer Res. 2005, 11, 1441–1446. [Google Scholar] [CrossRef] [Green Version]
- Ytting, H.; Christensen, I.J.; Thiel, S.; Jensenius, J.C.; Nielsen, H.J. Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2—A prognostic marker in colorectal cancer. Hum. Immunol. 2008, 69, 414–420. [Google Scholar] [CrossRef]
- Wang, J.; Gao, F.; Mo, F.; Hong, X.; Wang, H.; Zheng, S.; Lin, B. identification of CHI3L1 and MASP2 as a biomarker pair for liver cancer through integrative secretome and transcriptome analysis. Proteom. Clin. Appl. 2009, 3, 541–551. [Google Scholar] [CrossRef]
Molecule | Disease (Association) | References |
---|---|---|
Mannose-binding lectin (MBL) | Pancreatic cancer (elevated protein expression; proteomic analysis of serum) | [68] |
Collectin-10 (CL-10) | Hepatocellular carcinoma (decreased mRNA/protein expression) | [54] |
Colorectal cancer (low concentration in serum) | [96] | |
Collectin-11 (CL-11) | Lung adenocarcinoma (serum/urine concentration ratio) | [45] |
Ficolin-1 | Uterine corpus endometrial carcinoma (high FCN1 gene expression) | [38] |
Colorectal cancer (high concentration in serum) | [96] | |
Ficolin-2 | Uterine cervical cancer (high mRNA/protein expression) | [42,43] |
Oral cancer (elevated protein expression/proteomic analysis of serum) | [86] | |
Ficolin-3 | Ovarian cancer (elevated expression/proteomic analysis of serum) | [41] |
Lung adenocarcinoma (decreased FCN3 gene expression} | [30] | |
MASP-2 | Colorectal cancer (high concentration in serum) | [71,97,98] |
Non-small lung cancer (high concentration in serum) | [47] | |
Hepatocellular carcinoma (higher expression: transcriptome/secretome analysis; higher concentration in serum) | [99] | |
MAp44 | Colorectal cancer (low concentration in serum) | [96] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cedzyński, M.; Świerzko, A.S. Components of the Lectin Pathway of Complement in Solid Tumour Cancers. Cancers 2022, 14, 1543. https://doi.org/10.3390/cancers14061543
Cedzyński M, Świerzko AS. Components of the Lectin Pathway of Complement in Solid Tumour Cancers. Cancers. 2022; 14(6):1543. https://doi.org/10.3390/cancers14061543
Chicago/Turabian StyleCedzyński, Maciej, and Anna S. Świerzko. 2022. "Components of the Lectin Pathway of Complement in Solid Tumour Cancers" Cancers 14, no. 6: 1543. https://doi.org/10.3390/cancers14061543